Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Kernel regression based segmentation of optical coherence tomography images with diabetic macular edema
2015273 citationsMichael J. Allingham, Priyatham S. Mettu et al.profile →
Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities
2020237 citationsPriyatham S. Mettu, Michael J. Allingham et al.Progress in Retinal and Eye Researchprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Michael J. Allingham
Since
Specialization
Citations
This map shows the geographic impact of Michael J. Allingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Allingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Allingham more than expected).
Fields of papers citing papers by Michael J. Allingham
This network shows the impact of papers produced by Michael J. Allingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Allingham. The network helps show where Michael J. Allingham may publish in the future.
Co-authorship network of co-authors of Michael J. Allingham
This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Allingham.
A scholar is included among the top collaborators of Michael J. Allingham based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Michael J. Allingham. Michael J. Allingham is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Mettu, Priyatham S., Michael J. Allingham, & Scott W. Cousins. (2020). Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Progress in Retinal and Eye Research. 82. 100906–100906.237 indexed citations breakdown →
6.
Mettu, Priyatham S., Michael J. Allingham, & Scott W. Cousins. (2019). Effects of the Mitochondria-Targeted Drug Elamipretide on Leakage-Independent Vision Loss in Fellow Eyes with Neovascular AMD in the ReCLAIM Study. Investigative Ophthalmology & Visual Science. 60(9). 358–358.2 indexed citations
7.
Cousins, Scott W., Michael J. Allingham, & Priyatham S. Mettu. (2019). Elamipretide, a Mitochondria-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with Noncentral Geographic Atrophy: Results of the Phase 1 ReCLAIM Study. Investigative Ophthalmology & Visual Science. 60(9). 974–974.6 indexed citations
8.
Allingham, Michael J., Priyatham S. Mettu, & Scott W. Cousins. (2019). Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen: Results of the Phase 1 ReCLAIM Study. Investigative Ophthalmology & Visual Science. 60(9). 361–361.5 indexed citations
Mettu, Priyatham S., Michael J. Allingham, PETER C. NICHOLAS, & Scott W. Cousins. (2017). Adjunctive Indocyanine Green Angiography-Directed Verteporfin Photodynamic Therapy for the Treatment of Persistent Disease Activity in Neovascular AMD. Investigative Ophthalmology & Visual Science. 58(8). 1931–1931.1 indexed citations
Mettu, Priyatham S., Michael J. Allingham, PETER C. NICHOLAS, & Scott W. Cousins. (2016). Neovascular Morphology by ICG Angiography and Response to Loading-Dose Anti-VEGF Therapy in Patients with Neovascular AMD. Investigative Ophthalmology & Visual Science. 57(12).2 indexed citations
14.
Allingham, Michael J., Dibyendu Mukherjee, Hossein Rabbani, et al.. (2016). A quantitative approach to predict differential effects of anti-VEGF treatment on diffuse and focal leakage in patients with diabetic macular edema.. Investigative Ophthalmology & Visual Science. 57(12). 2076–2076.1 indexed citations
15.
Allingham, Michael J., Qing Nie, Eleonora M. Lad, et al.. (2015). Robust, easy-to-use, semiautomated software quantifies lesion rim area hyperautofluorescence and predicts progression of geographic atrophy.. Investigative Ophthalmology & Visual Science. 56(7). 2829–2829.1 indexed citations
16.
Zhang, Wenlan, PETER C. NICHOLAS, Stefanie Schuman, et al.. (2015). Screening for Diabetic Retinopathy Using the Hand-Held PICTOR Camera. Investigative Ophthalmology & Visual Science. 56(7). 1426–1426.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.